Oculis (NASDAQ:OCS - Get Free Report)'s stock had its "buy" rating restated by investment analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $30.00 price target on the stock. HC Wainwright's price target suggests a potential upside of 69.97% from the stock's current price.
Oculis Price Performance
NASDAQ:OCS traded up $0.09 during midday trading on Monday, hitting $17.65. 169,309 shares of the stock were exchanged, compared to its average volume of 112,603. The company has a market capitalization of $714.90 million, a price-to-earnings ratio of -9.15 and a beta of -0.33. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. Oculis has a one year low of $10.50 and a one year high of $18.10. The business has a 50-day moving average price of $16.33 and a two-hundred day moving average price of $13.79.
About Oculis
(
Get Free Report)
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
See Also
Before you consider Oculis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oculis wasn't on the list.
While Oculis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
